Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Scancell Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SCLP is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SCLP's weekly volatility has decreased from 13% to 7% over the past year.
7 Day Return
1 Year Return
Return vs Industry: SCLP exceeded the UK Biotechs industry which returned 29.5% over the past year.
Return vs Market: SCLP exceeded the UK Market which returned 22.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Scancell Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Scancell Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SCLP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SCLP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SCLP is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: SCLP is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SCLP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SCLP is overvalued based on its PB Ratio (6.8x) compared to the GB Biotechs industry average (5.4x).
How is Scancell Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCLP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SCLP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SCLP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SCLP's revenue is forecast to grow faster than the UK market.
High Growth Revenue: Insufficient data to determine if SCLP's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SCLP's Return on Equity is forecast to be high in 3 years time
How has Scancell Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SCLP is currently unprofitable.
Growing Profit Margin: SCLP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SCLP is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare SCLP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCLP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.8%).
Return on Equity
High ROE: SCLP has a negative Return on Equity (-27.73%), as it is currently unprofitable.
How is Scancell Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: SCLP's short term assets (£28.1M) exceed its short term liabilities (£7.0M).
Long Term Liabilities: SCLP's short term assets (£28.1M) exceed its long term liabilities (£68.0K).
Debt to Equity History and Analysis
Debt Level: SCLP's debt to equity ratio (13.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if SCLP's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SCLP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SCLP has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.9% each year
What is Scancell Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SCLP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SCLP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SCLP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SCLP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SCLP's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Prof. Lindy Gillian Durrant, Ph.D., has been the Chief Executive Officer of Scancell Holdings plc since July 28, 2021. She is the Founder of Scancell Holdings PLC and serves as its Chief Scientific Officer...
CEO Compensation Analysis
Compensation vs Market: Lindy's total compensation ($USD279.86K) is below average for companies of similar size in the UK market ($USD569.94K).
Compensation vs Earnings: Lindy's compensation has increased whilst the company is unprofitable.
Experienced Management: SCLP's management team is considered experienced (2.4 years average tenure).
Experienced Board: SCLP's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 75.2%.
Scancell Holdings plc's company bio, employee growth, exchange listings and data sources
- Name: Scancell Holdings plc
- Ticker: SCLP
- Exchange: AIM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£185.462m
- Shares outstanding: 815.22m
- Website: https://www.scancell.co.uk
Number of Employees
- Scancell Holdings plc
- John Eccles House
- Robert Robinson Avenue
- OX4 4GP
- United Kingdom
Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company’s product candidates include SCIB1, which is in phase II clinical trial fo...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 03:53|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.